Original article
Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study
Comparación de efectividad y persistencia del infliximab biosimilar CPT-13 versus infliximab de referencia en la enfermedad inflamatoria intestinal: Un estudio de cohorte retrospectivo
Lidia Serrano Díaza,d, Carles Iniesta Navalónb,d,
, Rosa Gómez Espína,d, Isabel Nicolás De Pradoa,d, Enrique Bernal Morellc,d, Lorena Rentero Redondob
Corresponding author
a Department of Gastroenterology, Reina Sofia Hospital of Murcia, Spain
b Department of Hospital Pharmacy, Reina Sofia Hospital of Murcia, Spain
c Department of Infectious Disease, Reina Sofia Hospital of Murcia, Spain
d Biomedical Research Institute of Murcia (IMIB-Pascual Parrilla), University Clinical Hospital Virgen de la Arrixaca, Murcia, Spain
Read
390
Timeswas read the article
119
Total PDF
271
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 5 | 4 | 9 |
| 2024 October | 8 | 19 | 27 |
| 2024 September | 11 | 15 | 26 |
| 2024 August | 6 | 2 | 8 |
| 2024 July | 8 | 4 | 12 |
| 2024 June | 25 | 17 | 42 |
| 2024 May | 23 | 14 | 37 |
| 2024 April | 10 | 10 | 20 |
| 2024 March | 12 | 12 | 24 |
| 2024 February | 15 | 5 | 20 |
| 2024 January | 14 | 1 | 15 |
| 2023 December | 15 | 0 | 15 |
| 2023 November | 13 | 1 | 14 |
| 2023 October | 30 | 4 | 34 |
| 2023 September | 13 | 2 | 15 |
| 2023 August | 63 | 9 | 72 |
Show all
